Back to Search Start Over

Adherence to a Mediterranean lifestyle improves metabolic status in coronary heart disease patients: A prospective analysis from the CORDIOPREV study.

Authors :
Romero-Cabrera JL
García-Ríos A
Sotos-Prieto M
Quintana-Navarro G
Alcalá-Díaz JF
Martín-Piedra L
Torres-Peña JD
Luque RM
Yubero-Serrano EM
Delgado-Lista J
Katsiki N
Kales SN
López-Miranda J
Pérez-Martínez P
Source :
Journal of internal medicine [J Intern Med] 2023 May; Vol. 293 (5), pp. 574-588. Date of Electronic Publication: 2023 Jan 11.
Publication Year :
2023

Abstract

Background and Objectives: A Mediterranean lifestyle may prevent and mitigate cardiometabolic disorders. We explored whether adherence to a Mediterranean lifestyle was prospectively associated with the risk of metabolic syndrome (MetS) among coronary heart disease (CHD) patients.<br />Methods: The Coronary Diet Intervention with Olive Oil and Cardiovascular Prevention (CORDIOPREV) study was an interventional diet study to compare a Mediterranean diet with a low-fat diet, in 1002 CHD patients. The Mediterranean lifestyle (MEDLIFE) index was used to assess adherence to a MEDLIFE at baseline, and after 5 years, in 851 participants from the CORDIOPREV study. Subjects were classified as having high (>13 points), moderate (12-13 points), and low (<12 points) adherence to the MEDLIFE. Multivariable logistic regression models were used to determine the association between MEDLIFE adherence and the risk of MetS development or reversal.<br />Results: During the 5-year follow-up, CORDIOPREV participants with high adherence to MEDLIFE had a lower risk of MetS development (odds ratio [OR] 0.37, 95% confidence interval [CI] 0.19-0.75, p < 0.01) and a higher likelihood of reversing preexisting MetS (OR 2.08 CI 95% 1.11-3.91, p = 0.02) compared with participants in the low MEDLIFE adherence group. Each additional one-point increment in the MEDLIFE index was associated with a 24% lower risk of MetS development (OR 0.76, 95% CI 0.64-0.90, p < 0.01) and a 21% higher likelihood of reversing preexisting MetS (OR 1.21 CI 95% 1.04-1.41, p = 0.01).<br />Conclusions: Our results showed that greater adherence to a MEDLIFE reduced the risk of subsequent MetS development and increased the likelihood of reversing preexisting MetS among patients with CHD at baseline.<br /> (© 2022 The Association for the Publication of the Journal of Internal Medicine.)

Details

Language :
English
ISSN :
1365-2796
Volume :
293
Issue :
5
Database :
MEDLINE
Journal :
Journal of internal medicine
Publication Type :
Academic Journal
Accession number :
36585892
Full Text :
https://doi.org/10.1111/joim.13602